Key result
Nadolol lowers blood pressure by ~34/21 mmHg in essential hypertension.
Why the study?
The efficacy and dose-response of nadolol, a new beta-adrenoceptor blocker with a long half-life, in essential hypertension were not established.
Effect estimate: reduction of 34/21 mmHg
May support nadolol dose exploration in hypertension; hypothesis-generating and should not yet change practice.
A preliminary, single-blind, dose-ranging study was carried out in 30 patients with essential hypertension to assess the efficacy of nadolol, a new beta-adrenoceptor blocking agent without intrinsic sympathomimetic action and with an extremely long plasma half-life. After a 2-week period on placebo, patients were treated for 14 weeks with daily doses of 40 mg nadolol (20 mg twice daily). Dosage was increased every second week up to a maximum of 560 mg daily or until the patient was stabilized at an effective normotensive dose level. The results showed that at the end of the trial period there was a significant reduction in both systolic and diastolic blood pressure (approximately 34/21 mmHg) at an average daily dose of 110 mg nadolol. Apart from a tendency to bradycardia, explained by the drug's lack of sympathomimetic action, no other side-effects attributable to treatment were reported and no patient complained of sleep disturbance.
No takes yet. Share an insight, caveat, or question.
G Frithz (1978) studied essential hypertension (n=30). nadolol vs. baseline was evaluated on reduction in systolic and diastolic blood pressure (reduction of 34/21 mmHg). Nadolol treatment in patients with essential hypertension resulted in a significant reduction in systolic and diastolic blood pressure of approximately 34/21 mmHg.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: